Chimeric Therapeutics
Chimeric Therapeutics is a results-driven cancer cell therapy company with a diversified portfolio including first-in-class autologous CAR T cell therapies and allogeneic NK cell therapies. Focused on discovery, development, and commercialization of innovative solutions, it aims to bring transformative therapies to patients with cancer. The company is led by a team of cell therapy pioneers and experts, and currently has four clinical trials in progress.
Industries
Nr. of Employees
small (1-50)
Chimeric Therapeutics
Carlton South, Victoria, Australia, Oceania
Products
Autologous CAR T therapy targeting CDH17
A third-generation autologous CAR T candidate targeting the CDH17 antigen, optimised with combined co-stimulatory domains and preclinical evidence of tumour eradication with limited normal tissue toxicity.
Peptide-targeted CAR T therapy for glioblastoma
An autologous CAR T approach using a short peptide targeting domain derived from a natural peptide to broaden and specify tumour recognition in glioblastoma.
Allogeneic NK cell therapy platform
An off-the-shelf NK cell therapy platform under clinical evaluation for haematological and solid tumour indications with early clinical validation.
Autologous CAR T therapy targeting CDH17
A third-generation autologous CAR T candidate targeting the CDH17 antigen, optimised with combined co-stimulatory domains and preclinical evidence of tumour eradication with limited normal tissue toxicity.
Peptide-targeted CAR T therapy for glioblastoma
An autologous CAR T approach using a short peptide targeting domain derived from a natural peptide to broaden and specify tumour recognition in glioblastoma.
Allogeneic NK cell therapy platform
An off-the-shelf NK cell therapy platform under clinical evaluation for haematological and solid tumour indications with early clinical validation.
Services
Early-phase clinical trial management
End-to-end management of Phase 1 / 1b trials including protocol implementation, site engagement and dose-escalation operations.
Preclinical development and target validation
Antigen discovery, antibody development and in vitro/in vivo validation studies to support candidate selection.
Cell therapy process development and manufacturing support
Development and optimisation of autologous manufacturing workflows including leukapheresis handling, engineering and expansion processes for clinical product supply.
Regulatory strategy and engagement support
Regulatory planning and interactions with authorities to pursue expedited pathways and support clinical advancement.
Commercialisation planning and partnership development
Business development activities to enable rapid commercial translation and partner collaborations.
Early-phase clinical trial management
End-to-end management of Phase 1 / 1b trials including protocol implementation, site engagement and dose-escalation operations.
Preclinical development and target validation
Antigen discovery, antibody development and in vitro/in vivo validation studies to support candidate selection.
Cell therapy process development and manufacturing support
Development and optimisation of autologous manufacturing workflows including leukapheresis handling, engineering and expansion processes for clinical product supply.
Regulatory strategy and engagement support
Regulatory planning and interactions with authorities to pursue expedited pathways and support clinical advancement.
Commercialisation planning and partnership development
Business development activities to enable rapid commercial translation and partner collaborations.
Expertise Areas
- Cell therapy development
- Autologous CAR T therapy
- Allogeneic NK cell therapy
- Early-phase clinical trial management
Key Technologies
- Autologous CAR T cell therapy
- Allogeneic NK cell therapy platform
- Chimeric antigen receptor engineering (multi-costimulatory domains)
- Peptide-based tumour-targeting domains